Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 9/20 | 0.46 |
| ▸ | PKLR | P30613 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | USP9X | Q93008 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391138 | 0.83 | PKM (0.54) | PKMPKLRNPC1RAB9ALMNA | |
| SCHEMBL4381279 | 0.81 | PKM (0.49) | ALDH1A1PKMLMNAKDM4E | |
| SCHEMBL4385228 | 0.79 | PKM (0.44) | ALDH1A1PKMPKLRLMNA | |
| SCHEMBL4392624 | 0.78 | GAA (0.40) | ALDH1A1PKMPKLRLMNACYP2C19 | |
| SCHEMBL4393934 | 0.78 | PKM (0.58) | HTTALDH1A1PKMLMNACYP2C19 | |
| SCHEMBL4393768 | 0.77 | KMT2A (0.47) | PKMPKLRNPC1 | |
| SCHEMBL4391478 | 0.76 | PKM (0.52) | HTTALDH1A1PKMPKLRNPC1 | |
| SCHEMBL4382575 | 0.76 | KMT2A (0.52) | HTTALDH1A1PKMLMNA | |
| SCHEMBL4380728 | 0.75 | GAA (0.51) | ALDH1A1PKMKDM4E | |
| SCHEMBL4379004 | 0.74 | SCN9A (0.44) | ALDH1A1SCN9APKMPKLRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | HTT 4042/4885ALDH1A1 2105/4885RECQL 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.